A scoring system established by Nunes et al, 2022 was used to determine HER2 expression: 0 = no membrane staining or incomplete and faint/barely perceptible membrane staining in ≤10% of tumor cells; 1+ = incomplete and faint/barely perceptible membrane staining in ≥10% of tumor cells; 2+ = incomplete and/or weak/moderate membrane staining in >10% of tumor cells or complete and intense membrane staining in ≤10% of tumor cells; and 3+ = complete and intense membrane staining in >10% of tumor cells). Here, ERBB2 is linked to neoplasm.